Intestinal Cancer
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Intestinal Cancer is a moderately active landscape with 83 programs across 41 companies. The most active players are Eastern Cooperative Oncology Group, Boehringer Ingelheim, COMPASS Pathways. 1 therapy is approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Eastern Cooperative Oncology Group
2 programs
Boehringer Ingelheim
1 program
COMPASS Pathways
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
Shuttle Pharmaceuticals, Inc.
1 program
CNBG-Virogin Biotech (Shanghai) Ltd.
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
82%
Small molecule
75 of 91 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 91 classified programs, each share of the total. Modality classified for 100% of 95 pipeline programs.
Analysis
Trial Status
62
clinical trials
Clinical Trials
Trial Activity
62 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)